Display options
Share it on

Am J Transl Res. 2017 Sep 15;9(9):4308-4316. eCollection 2017.

MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia.

American journal of translational research

Dan Chen, Dijiong Wu, Keding Shao, Baodong Ye, Jian Huang, Yanting Gao

Affiliations

  1. Department of Hematology, Fourth Affiliated Hospital, School of Medicine, Zhejiang UniversityYiwu, China.
  2. Department of Hematology, First Affiliated Hospital of Zhejiang Chinese Medical UniversityHangzhou, China.

PMID: 28979704 PMCID: PMC5622273

Abstract

Chronic myeloid leukemia (CML) is a common malignant disease from hematopoietic system. Aberrant expression of microRNAs (miRNAs) has been found in CML, however, the roles of many miRNAs including miR-15a-5p in CML are still unknown. In this study, the expression and roles of miR-15a-5p in CML were investigated. We found that restoration miR-15a-5p expression in CML cells decreased cell growth, metastasis and enhanced cell apoptosis. Chemokine ligand 10 (CXCL10) was predicted as a target gene of miR-15a-5p, which was verified by luciferase assay. CXCL10 mRNA and protein was down-regulated in the CML cells with miR-15a-5p overexpression by real time RT-PCR and western blotting. We also found that there were low levels of miR-15a-5p companied with high levels of CXCL10 in blood samples from CML patients. In a conclusion, miR-15a-5p suppresses cell survival and metastasis of CML by targeting CXCL10, which is a therapeutic option for CML patients.

Keywords: CXCL10; MiR-15a-5p; chronic myeloid leukemia; metastasis

Conflict of interest statement

None.

References

  1. Oncotarget. 2015 Sep 22;6(28):24978-89 - PubMed
  2. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Dec;158(4):489-501 - PubMed
  3. Mol Cytogenet. 2013 Jul 16;6(1):27 - PubMed
  4. Sci Rep. 2015 Jul 31;5:12460 - PubMed
  5. Leuk Res. 2013 Mar;37(3):349-56 - PubMed
  6. Breast Cancer Res Treat. 2014 May;145(1):73-82 - PubMed
  7. Curr Hematol Malig Rep. 2013 Mar;8(1):28-36 - PubMed
  8. Mol Clin Oncol. 2016 Jan;4(1):23-30 - PubMed
  9. Oncotarget. 2014 Nov 30;5(22):11064-80 - PubMed
  10. Mol Cancer. 2015 Nov 06;14:190 - PubMed
  11. Cancer Lett. 2015 May 1;360(2):245-56 - PubMed
  12. Virology. 2014 May;456-457:319-28 - PubMed
  13. Oncotarget. 2015 Feb 20;6(5):2981-91 - PubMed
  14. Oncotarget. 2015 Jan 20;6(2):1249-61 - PubMed
  15. Curr Hematol Malig Rep. 2011 Jun;6(2):82-7 - PubMed
  16. Leuk Lymphoma. 2011 Feb;52 Suppl 1:30-44 - PubMed
  17. J Transl Med. 2013 Oct 23;11:265 - PubMed
  18. Oncotarget. 2016 May 10;7(19):27394-407 - PubMed
  19. Blood. 2015 Feb 19;125(8):1302-13 - PubMed
  20. Oncotarget. 2016 Jul 5;7(27):42683-42697 - PubMed
  21. Tumour Biol. 2016 May;37(5):5821-8 - PubMed
  22. Cell Mol Life Sci. 2015 Jun;72(12):2337-47 - PubMed
  23. Oncoimmunology. 2015 Apr 2;4(9):e1027473 - PubMed
  24. Tumour Biol. 2015 Jan;36(1):437-46 - PubMed

Publication Types